{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:53:08Z","timestamp":1791910388790,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.vaccine.2026.129177","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:14:55Z","timestamp":1790068495000},"page":"129177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["LP.8.1-directed recombinant protein COVID-19 vaccine S-268025, formulated with squalene-based adjuvant A-910823, elicits robust immunogenicity and neutralizing breadth in mice"],"prefix":"10.1016","volume":"93","author":[{"given":"Shouta","family":"Saiki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Kuroiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nakajima-Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Susai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Hamana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Nikaido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Toyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Kunita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Yamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Kinuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kugimiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Rokushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Omoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.vaccine.2026.129177_bb0005","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.vaccine.2026.129177_bb0010","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.vaccine.2026.129177_bb0015","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.vaccine.2026.129177_bb0020","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129177_bb0025","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.cell.2021.04.006","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129177_bb0030","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129177_bb0035","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.cell.2022.03.037","article-title":"Boosting with variant-matched or historical mRNA vaccines protects against omicron infection in mice","volume":"185","author":"Ying","year":"2022","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129177_bb0040","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.cell.2022.03.038","article-title":"mRNA-1273 or mRNA-omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from omicron","volume":"185","author":"Gagne","year":"2022","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129177_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115543","article-title":"Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC","volume":"44","author":"Wang","year":"2025","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.vaccine.2026.129177_bb0050","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1473-3099(25)00308-1","article-title":"Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1","volume":"25","author":"Guo","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129177_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101165","article-title":"Host cell entry and neutralisation sensitivity of SARS-CoV-2 BA.3.2","volume":"6","author":"Zhang","year":"2025","journal-title":"Lancet Microbe"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129177_bb0060","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S1473-3099(25)00658-9","article-title":"Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2","volume":"26","author":"Zhang","year":"2026","journal-title":"Lancet Infect Dis"},{"issue":"31","key":"10.1016\/j.vaccine.2026.129177_bb0065","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1016\/j.vaccine.2022.05.081","article-title":"Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys","volume":"40","author":"Hashimoto","year":"2022","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2026.129177_bb0070","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1016\/j.vaccine.2022.10.092","article-title":"Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 omicron subvariants in cynomolgus macaques","volume":"40","author":"Hashimoto","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129177_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25418-5","article-title":"Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice","volume":"12","author":"Homma","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.129177_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1116238","article-title":"A-910823, a squalene-based emulsion adjuvant, induces T follicular helper cells and humoral immune responses via \u03b1-tocopherol component","volume":"14","author":"Yoshioka","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.129177_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126780","article-title":"A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets","volume":"49","author":"Hashimoto","year":"2025","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129177_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-026-01420-0","article-title":"IL-1 delineates squalene-based adjuvant efficacy and reactogenicity in a cell-type-specific manner","volume":"11","author":"Yoshioka","year":"2026","journal-title":"NPJ Vaccines."},{"issue":"27","key":"10.1016\/j.vaccine.2026.129177_bb0095","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1016\/j.vaccine.2022.04.054","article-title":"Phase 1\/2 clinical trial of COVID-19 vaccine in Japanese participants: a report of interim findings","volume":"40","author":"Iwata","year":"2022","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2026.129177_bb0100","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1016\/j.vaccine.2022.06.032","article-title":"Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: an interim report of phase 2\/3, randomized, observer-blinded, noninferiority study","volume":"40","author":"Shinkai","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129177_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2023.100390","article-title":"Safety and immunogenicity of a booster dose of S-268019-b: interim findings of a phase 3, open-label clinical study in Japan","volume":"15","author":"Sonoyama","year":"2023","journal-title":"Vaccine X"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129177_bb0110","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41467-023-37128-1","article-title":"Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain","volume":"14","author":"Takano","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.129177_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1550279","article-title":"Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1\/2 prime-boost study","volume":"16","author":"Fujitani","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129177_bb0120","doi-asserted-by":"crossref","first-page":"9830","DOI":"10.1038\/s41598-024-57308-3","article-title":"A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults","volume":"14","author":"Iwata","year":"2024","journal-title":"Sci Rep"},{"issue":"49","key":"10.1016\/j.vaccine.2026.129177_bb0125","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.46234\/ccdcw2021.255","article-title":"GISAID\u2019S role in pandemic response","volume":"3","author":"Khare","year":"2021","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.vaccine.2026.129177_bb0130","series-title":"Racmacs: antigenic cartography macros","author":"Wilks","year":"2022"},{"key":"10.1016\/j.vaccine.2026.129177_bb0135","series-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2023"},{"issue":"5682","key":"10.1016\/j.vaccine.2026.129177_bb0140","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.1097211","article-title":"Mapping the antigenic and genetic evolution of influenza virus","volume":"305","author":"Smith","year":"2004","journal-title":"Science"},{"issue":"8018","key":"10.1016\/j.vaccine.2026.129177_bb0145","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41586-024-07539-1","article-title":"Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines","volume":"630","author":"Liang","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.129177_bb0150","series-title":"Statement on the antigen composition of COVID-19 vaccines","author":"WHO","year":"2025"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129177_bb0155","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S1473-3099(25)00772-8","article-title":"Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2","volume":"26","author":"Kaku","year":"2026","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129177_bb0160","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1038\/s41467-021-23977-1","article-title":"Immunological imprinting of the antibody response in COVID-19 patients","volume":"12","author":"Aydillo","year":"2021","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129177_bb0165","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41564-023-01505-9","article-title":"Immune imprinting and next-generation coronavirus vaccines","volume":"8","author":"Huang","year":"2023","journal-title":"Nat Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129177_bb0170","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.immuni.2023.04.012","article-title":"Immunological imprinting: understanding COVID-19","volume":"56","author":"Koutsakos","year":"2023","journal-title":"Immunity"},{"issue":"29","key":"10.1016\/j.vaccine.2026.129177_bb0175","doi-asserted-by":"crossref","first-page":"17221","DOI":"10.1073\/pnas.1920321117","article-title":"Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies","volume":"117","author":"Arevalo","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2026.129177_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127393","article-title":"The impact of egg adaptation and immune imprinting on influenza vaccine effectiveness","volume":"62","author":"Ashraf","year":"2025","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129177_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2026.117052","article-title":"Repeated COVID-19 vaccine boosters elicit variant-specific memory B cells in humans","volume":"45","author":"Tortorici","year":"2026","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129177_bb0190","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/S1473-3099(26)00050-2","article-title":"Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters","volume":"26","author":"Lasrado","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129177_bb0195","article-title":"LP81-directed COVID-19 mRNA vaccines durably boost neutralizing antibodies and mitigate ancestral immune imprinting","author":"Mellis","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2026.129177_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2026.128871","article-title":"Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study","volume":"88","author":"Nakano","year":"2026","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129177_bb0205","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02901-25","article-title":"Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination","volume":"17","author":"Abbad","year":"2026","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2026.129177_bb0210","series-title":"Statement on the antigen composition of COVID-19 vaccines","author":"WHO","year":"2026"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:25:07Z","timestamp":1791908707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26009862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":42,"alternative-id":["S0264410X26009862"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129177","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LP.8.1-directed recombinant protein COVID-19 vaccine S-268025, formulated with squalene-based adjuvant A-910823, elicits robust immunogenicity and neutralizing breadth in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129177"}}